FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast CancerLaleh Amiri‐Kordestani, Patricia Cortazar, Shenghui Tang et al.|Clinical Cancer Research|2014Cited by 350
First FDA Approval of Dual Anti-HER2 Regimen: Pertuzumab in Combination with Trastuzumab and Docetaxel for HER2-Positive Metastatic Breast CancerGideon M. Blumenthal, Richard Pazdur, Nancy S. Scher et al.|Clinical Cancer Research|2013Cited by 120